AbbVie's VIEKIRAX(R) (ombitasvir/paritaprevir/ritonavir tablets) Receives Approval in Japan for the Treatment of Genotype 1 Chronic Hepatitis C

New interferon and ribavirin-free treatment option for patients with most common type of hepatitis in Japan, genotype 1 chronic hepatitis C, including those with compensated cirrhosis[1] VIEKIRAX consists of a 12-week, two direct-acting antiviral, fixed... Biopharmaceuticals, RegulatoryAbbVie, VIEKIRAX, ombitasvir, paritaprevir, ritonavir
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news